Bexion Pharmaceuticals, Inc. to Participate in the 2023 Cantor Global Healthcare Conference

COVINGTON, Ky., Sept. 25, 2023 /PRNewswire/ — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 2023 Cantor Global Healthcare Conference. The conference will be held in New York, NY, from September 26-28, 2023.

Scott Shively, CEO and President of Bexion Pharmaceuticals, will be presenting a company overview at the conference on September 27, 2023, at 4:45 – 5:15 p.m. ET in Track 2.

About Bexion Pharmaceuticals
Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion currently has three clinical trials open for enrollment.

Investor Contact:
William Windham
Solebury Strategic Communications
646-378-2946
[email protected]

Media Contact:
Joyce LaViscount
Bexion Pharmaceuticals
859-446-7386
[email protected]